# PCSK9 inhibitors

Drug · id `cardio:pcsk9-inhibitors` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Proprotein convertase subtilisin kexin type 9 inhibitors

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease  

## In plain language

PCSK9 inhibitors are cholesterol medicines that block a protein called PCSK9. MedlinePlus says this helps the liver remove and clear LDL cholesterol from the blood. The US labels of alirocumab and evolocumab each call the product a PCSK9 inhibitor, and both have their own pages. A third cholesterol medicine acts on the messenger RNA for PCSK9 instead and is linked here, not filed under the class. This is the class page.

## Technical summary

Class page. MeSH descriptor D000091362 (PCSK9 Inhibitors, lastUpdated 2022-01-01) is an exact match; its scope note says these agents inhibit the PCSK9 enzyme, which has an important role in degrading LDL receptors, and that they favor LDL catabolism and lower plasma LDL cholesterol. The US labels read for alirocumab (BLA125559) and evolocumab (BLA125522) call each product a PCSK9 inhibitor, and RxClass lists the established pharmacologic class PCSK9 Inhibitor on US drug labels for both (read 2026-11-18); alirocumab and evolocumab are filed under this page on that evidence. The US label of a third PCSK9-directed medicine (NDA214012), a small interfering RNA, says it directs breakdown of the mRNA for PCSK9, and RxClass returned no class for it, so it has a related link only. MedlinePlus names these medicines together with another cholesterol class that has its own page. No trial result and no dose is recorded.

## Connected pages

- Files under this front: Medicines (`cardio:front-medicines`)
- MeSH: agents that inhibit PCSK9: PCSK9 (gene and protein) (`cardio:pcsk9`)
- MedlinePlus lists PCSK9 inhibitors among cholesterol medicines: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- MeSH and MedlinePlus: PCSK9 inhibitors lower LDL cholesterol: High LDL cholesterol (`cardio:high-ldl-cholesterol`)
- MedlinePlus names familial hypercholesterolemia where it discusses PCSK9 inhibitors: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- MedlinePlus names a PCSK9 inhibitor and a statin together: Statins (`cardio:statins`)
- Acts on the messenger RNA for PCSK9 (label wording); not filed under this class: Inclisiran (`cardio:inclisiran`)
- Has subtype: Alirocumab (`cardio:alirocumab`)
- Has subtype: Evolocumab (`cardio:evolocumab`)

## Provenance

Content hash: 00f20ae3bab6714ae2340cf5380f759c81f3889640244a3657f39ef375a337a1
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
